This is a case-based activity that includes discussion of a 36-year-old woman who originally presented at 18 weeks gestation with clinical T2N0, grade 3 invasive ductal carcinoma of the right breast. The tumor was ER+, PR+, and HER2 negative.
- Explain how to incorporate recent evidence-based guideline recommendations and new data to select first-line therapy for women with hormone sensitive advanced breast cancer
- Describe the evolving role of ovarian suppression in the treatment of premenopausal women with early or advanced hormone sensitive breast cancer
- This course expires on October 28, 2019. Participants must complete all necessary course components by this date.
- This course is available as part of the 2016 ASCO Tumor Boards bundle.